Blogs | MedChemExpress

FPA-124 is a Selective Akt Inhibitor and Induces Apoptosis

FPA-124 is a cell-permeable copper complex and a selective Akt inhibitor. FPA-124 induces apoptosis in multiple human cancer cells.
PI-828 is a Dual PI3K and Casein Kinase 2 Inhibitor

PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with good anti-cancer activity. PI-828 mitigated radiation-induced apoptosis in NCCIT cells.
MS432 is a Highly Selective PROTAC Degrader for MEK1 and MEK2

MS432 is a first-in-class and highly selective PD0325901-based VHL-recruiting PROTAC degrader for MEK1 and MEK2 with good anti-cancer activity.
UK 356618 is a Selective MMP-3 Inhibitor

UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity.
DRF-1042 is an Orally Active DNA topoisomerase I Inhibitor

DRF-1042 is an orally active derivative of Camptothecin and acts to inhibit DNA topoisomerase I with good anticancer activity.
TK216 is an ETS Transcription Factor Inhibitor for Treatment of Ewing Sarcoma

TK216 is a potent ETS inhibitor. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity.
MG-277, a PROTAC Molecular Glue, Exhibits Anti-cancer Activity by Inhibiting GSPT1

MG-277 works as a PROTAC molecular glue, inducing degradation of a translation termination factor, GSPT1 to achieve its potent anticancer activity.
Niraparib is an Orally Active PARP Inhibitor

Niraparib is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor. Niraparib has potent anti-cancer activity.
Alpelisib is a Selective and Orally Active PI3Kα Inhibitor for Metastatic Breast Cancer

Alpelisib is a potent, selective, and orally active PI3Kα inhibitor (IC50=5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, p110δ, and p110β).
Telaglenastat is a Selective and Orally Active Inhibitor of Glutaminase 1

Telaglenastat is a first-in-class, reversible, orally bioavailable glutaminase 1 splice variants (KGA and GAC) inhibitor. It shows antitumor activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (19)